Dr. Shrikant Mishra

• ORF optimization for E coli and mammalian expression (RNA secondary structure, enthalpy), Generation of E coli MCB (master cell bank) and clone validation, Generation of mammalian MCB and clone validation
• Special assays : G-PCR assays, clonogenic assays, kinase assays, check point assays, SPR assays. Novel discovery bioassay development (platforms : cell culture, ELISA, fluorescence, flow cytometry, radioactive)
• Fermentation batch validation (pcd, volumetric production, O2, pH, Temp, anti-foam, acetate), High level soluble expression / targeted expression, Trouble shooting ion-exchange chromatography, HIC, GPC, EBA, and HPLC (method development, critical parameters, chromatographic scale up, and validation)
• Trouble shooting analytical method development and validation (sds-page, western blot, southern blot, PCR, 2D western, TLC, HPLC, LC-MS etc.), Forced degradation, half life, and Potency validation
• Trouble shooting formulation method development and validation, Technology Transfer

• CBSE, Bharatiya Vidya Bhavan, Kasturba Gandhi Marg, New Delhi, 1977
• BSc Physics, St Stephen’s College, Delhi University, 1980
• MSc Physics, St. Stephen’s college, Delhi University, 1982
• Instructor, St. Stephen’s college, Delhi University, 1983-4
• Instructor, Hindu college, Delhi University1984-5
• Instructor, Regional College Of Engineering, Bhubaneswar, Odisha1985
• Instructor, Maharshi College, Bhubaneswar, Odisha 1985
• Graduate Student, Biochemistry, Virginia Maryland Regional College Of Veterinary Medicine, Virginia Tech, U.S.A 1986
• Research Fellow, Virginia Maryland Regional College Of Veterinary Medicine, Virginia Tech, U.S.A 1992
• Research Fellow, University of Maryland Cancer Center, U.S.A 1993
• Senior Fellow, Mayo Clinic, U.S.A 1994
• Head, Biotechnology Research Laboratory, USV Ltd, India(1996-2010)
• Consultant, Sun Pharmaceuticals, Vadodara, India (2011-13)
• Head, Technology Translation Research Laboratory, Kiit School Of Biotechnology, Bhubaneswar, India(2013-present)

• CART  Therapy Product——————————–(Enquire)
• Clopidrogel ——————————————-Anti-platelet/Delivered aggregation assay system for marketed samples
• Famcyclovir——————————————-For herpes/Product and process developed at 1.0 kg , lab scale
• Simvastatin——————————————-Anti-cholesterol/Product developed from lovatatin at 1.0 kg, lab scale
• Acarbose———————————————-Obesity/From clone to process at 1 lit

• Eptifibatide——————————————–Anti-platelet/From lab to launch, produced by solid phase synthesis
• Bivalirudine——————————————-Anti-platelet /From lab to launch , produced by solid phase synthesis
• Octreotide———————————————Anti-cancer/From lab to launch , produced by solid phase synthesis

• hGH—————————————————–Turner’s syndrome/From clone to human phase III
• G-CSF—————————————————Anti-cancer/From clone to pre-clinical, animal
• PEG-G-CSF———————————————Anti-cancer/From clone to pre-clinical, animal
• PTH——————————————————Osteoporosis/From clone to human phase III
• PDGF—————————————————-Diabetes / topical/From clone to human phase III
• Neseritide——————————————— CHF/From clone to human phase III
• IL-2——————————————————-Anti-cancer/From clone to scale up
• Lucentis————————————————-Macular degeneration/Clone to R&D process
• Aranesp————————————————-Anemia/Cloned development

• Two component sanitizer—————————Sanitizer, d-odorizer/Completed product and technology development
• MEG-CO feel——————————————Anti-flu/Completed product and technology development
• IMAK—————————————————-Anti-pain/Completed product and technology development

96% in MCATs (all USA examination), GRE Verbal: 151/170, GRE Quant: 159/170. Vector-Host Platforms in E Coli and CHO systems, Cloned ~ 52 genes in E. Coli platform, Cloned ~ 34 genes in CHO platform, ~ 15 years of industry experience, ~ 31 years of biotechnology experience, 24 International Patents, 34 International Publications, 3 books published, 17 MTech Thesis , 5 Industry related theory courses  for MTech, Biotechnology,  3 Industry related practical courses for MTech, Biotechnology, 4 products crossed human phase-III trials,  12 products technologies developed end to end,  3 synthetic peptide products in ICU (Eptifibatide, Bivalirudine, Octreotide), ~ 500 analytical / bio analytical methods scaled up. Products delivered end to end being : rhG-CSF, PEG-G-CSF, Eptifibatide,  Octreotide, Bivalirudine, rEK, , rHGH, rPTH(1-34). Train more than 150 MTech students per year (2013-present). As Head Of Research Took company from 127 Cr to 1500 Cr in 14 years. Seven products delivered end to end in the clinic ( three in ICU), 1500 students into the market.

• Products Delivered to the clinic : rhG-CSF, PEG-G-CSF, Eptifibatide, Octreotide, Bivalirudine, rEK, rHGH, rPTH(1-34)
• Marketted Products : rhG-CSF, PEG-G-CSF, Eptifibatide,  Octreotide, Bivalirudine, rEK.
• Clinical Trial (human Phase III): recombinant hGH, recombinant PTH(1-34), rhPDGF-BB, rh Neseitide
• Approved preclinical Trials : recombinant hG-CSF (India), recombinant PEG-G-CSF (EU)

• Mesenchymal stem cells therapy in the control of long-term organ toxicity in COVID-19 infection (Asian J. of Pharmaceutical Sciences. Submitted, 2022)
• Exosomes manufacturing and development (MTech Thesis,  May  2022)
• Validation environment of mesenchymal stem cells. ( MTech Thesis,  May  2021)
• Comparative Quality assurance of Moderna and Pfizer Covid-19 vaccines. (MTech Thesis,  May  2021)
• Comprehensive study on substance abuse and addiction in subjects to develop promising targets and novel pharmacotherapy targets to treat SUDs. (MTech Thesis,  May  2020)
• Why do anti-fungals fail at primary phase ( MTech Thesis, May 2020)
• A Rapid Drug Sensitivity Evaluation  For  Azithromycin In Patients (MTech Thesis, April 2019)
• Mechanism of Kanamycine drug resistance (MTech Thesis, April 2019)
• QSAR of ZAP 70 Signalling (MTech Thesis, April 2018)
• Relevance of pre-grant opposition to project management (MTech Thesis, April 2018)
• Designing a protocol to increase Shelf Life (MTech Thesis, April 2018)
• Field stability tests for polymeric container closure (MTech Thesis, April 2018)
• Relevance of pre-grant opposition to start ups  ( MTech Thesis , April 2017 )
• Topical formulation for viral infection, MEG-Co-feel ( MTech Thesis ,April 2015)
• Novel topical formulation for neuro and muscular pain, IMAK ( MTech Thesis ,April 2015)
• Of Regulated Bio-marker Platforms , p62, 1^st International Conference On Translational Research, from basic science to clinical application (2015)
• Patent Application (2015, submission date : 07/02/2015) : Two components skin sanitizing/moisturizing system
• US20090035815: Synthetic Gene For Enhanced Expression In E. Coli
• WO2009019715: Novel Orthogonal Process For Purification Of Recombinant Human Parathyroid Hormone (Rhpth) (1 34)
• WO2009005973:Synthetic Gene For Enhanced Expression In E.Coli
• WO2008136014: Cloning And Expression Of Enterokinase And Its Process For Production
• US20070249806: Solid Phase Fmoc Chemistry Process To Prepare Peptides
• KR1020070083387: A Novel Process For Purification Of Human Growth Harmone
• CA2641372: Affinity Polypeptide For Purification Of Recombinant Proteins KR20070094902:Low Cell Density Fermentation Process For The Production Of Heterologous Recombinant Proteins In Microorganisms
• KR20070083387: A Novel Process For Purification Of Human Growth Hormone
• EP1758933: Chimeric Human Growth Hormone Derived From The Placenta And Pituitary Isoform And Processes For Obtaining Said Chimera
• WO2006051554: A Novel Process For Purification Of Human Growth Hormone
• CA2589716: Low Cell Density Fermentation Process For The Production Of Heterologous Recombinant Proteins In Microorganisms
• CA2565209: A Novel Process For Purification Of Human Growth Hormone
• CA25 AU2004324756: A Novel Process For Purification Of Human Growth Hormone
• AU2004320986: Chimeric Human Growth Hormone Derived From The Placenta And Pituitary Isoform And Processes For Obtaining Said Chimera
• 60007: Process For The Preparation Of Peptides
• AU2004320599: Process For The Preparation Of Peptides
• WO2006001027: Chimeric Human Growth Hormone Derived from the Placenta and Pituitary Isoform and Process for obtaining the same.
• WO 2006/05/554 : A Novel Process For Purification of Human Growth Hormone
• WO 2006067793 : Low Cell Density Fermentation Process for the production of Hetrologous Recombinant protein in Microorganisms.
• WO2005121164 : A process for the preparation of peptides
• WO2007096899: Affinity Polypeptide for Purification of recombinant protein
• US2007249806 : Solid Phase FMOC Process to Prepare Peptides
• PCT/IN/2007/000277 : Cloning and expression of enterokinase and it’s process for production
• 247 / MUM/2007 : Synthetic gene for enhanced expression in E. Coli
• 1543 / MUM/2007/ : Novel orthogonal process for the purification of recombinant human parathyroid hormone rhPTH (1-34)
• 1776/MUM/2007: An improved process for FMOC synthesis of Ecosapeptide
• Association of inhibition of cell growth by O-phospho-L-Tyr with decreased tyrosine phosphorylation.. Cancer Letters. 1996, 102(1-2): 65-71
• A microtiter assay for Cu/Zn and Mn- superoxide dismutase. Ind. J. Biochem. Biophys. 1996 (vol 33, 1996, pp319-322)
• A spin decay assay for tumor necrosis factor cytoxicity. Ind. J. Biochem. Biophys. 32, 254-260, 1995
• Regulation of the suspected tumor suppressor gene product CLP in human breast epithelial cells. J. Cell. Biochem. 18 (Supp):171
• Regulation of expression and search for specific tumor suppressor gene product. Mini paper, 3rd European Symp. On Ca Binding Proteins. Zurich, Switzerland, march 6-9, 1994
• Modulation of the cytotoxicity activity of tumor necrosis factor by protein tyrosine kinase and protesin tyrosine phosphatise inhibitors. Lymphokine & cytokine Research. 13(2), 77-83, 1994.
• Interferon –gamma induced reduction in erb B-2 Tyrosyl Phosphorylation in human ovarian carcinoma cells. Int. J. Cancer, 58, 538-542, 1994.
• A case of recurrent eclampsia.Post grad. Med. J. 1994, 70(828):769.
• A microtiter enzyme linked immunosorbent assay for protein tyrosine phosphatise. Biochem. Biophys. Acta. 1157: 93-101, 1993.
• Exogenous phosphotyrosine modulates epidermal growth factor receptor tyrosine phosphorylation. Carcinogenisis 14 : 273, 1993
• O-Phospho-L-Tyr inhibits cell growth by activating protein tyrosine phosphatises. Cancer Research. 53 : 557-563, 1993.
• Role of intracellular Ca++ in the epidermal growth factor induced inhibition of protein tyrosine phosptahaase activity in a breast cancer cell line. Biochem. Biophys. Res. Commun., 191: 1065-1072, 1993.
• Interferon enhancement of tyrosine phosphorylation of epidermal growth factor receptors in human breast carcinoma cells. Anticancer Res. 13, 613-618, 1993.
• O-phospho-L-tyr inhibits cellular growth by activating protein tyrosine phosphatises. Keystone Symposia on Signalling, Keystone , CO, 1993
• Preclampsia J. Perinatol, 1993, 13(5): 417-8
• Regulation of suspected tumor suppressor gene product CLP in human breast epithelial cells. Keystone Symposia on Tumor Suppressor Genes. Taos, NM, 1994
• O-phospho-L-tyr inhibits cellular growth by activating protein tyrosine phosphatises.J. Cell. Biochem. Suppl. 17A, BZ 624, 1993
• Regulation of tyrosine phosphorylation of epidermal growth factor in breast cancer cell lines by gamma-interferon.  Proceedings of 83rd Annual Meeting of the American Association for Cancer Research 33: 3(14), 1992.
• Microtiter enzyme linked immunosorbent assay for protein tyrosine phosphatise. World Congress of Cell and tissue Culture Washington DC, 1992.
• Mechanism of TNF-alpha cytotoxicity in a retrovial transformation model. Ph.D Thesis ( 1991)
• Tumor necrosis factor modulates tyrosine phosphorylation of A-MuLV specific cell surface antigen. 7251, FASEB J. 5(6): 1619, 1991.
• EPR observation of TEMPO quenching in monitoring TNF alpha cytotoxicity in L929 cells. Rocky Mountain Conference on Analytical Chemistry, 1991.
• Role of free radicals during reperfusion injury in isolated rat lungs. American Physiological Society Conference Proceedings, 1990.
• Reversal of superoxide dismutase reaction as detected by EPR spin trapping techniques. Conference proceedings of Federation of American Society of Experimental Biology. 2115, 1990.
• Regulation of manganese superoxide dismutase in endothelial cells. J. Cell. Biol. 107: 217a, 1989.
• Mechanism of microwave induced membrane damage in human erythrocytes. J. cell. Biol. 107, 188a, 1989
• Broken symmetry of biomolecules. Biophysical. J. , 151; 96a, 1987.    

Member, Bhavanite, Bharatya Vidya Bhavan Alumni(1977-current)

Member, St. Stephens College Alumni(1982-current)

Member, Mayo Clinic Alumni(1994-current)

Member, Indian Science Congress (2013-present)

Jury, Biotech Projects, Confederation Of Indian Industries (C.I.I)(2013-current)

Advisor, Technology Commercialization Facilitation Agency (T.C.F.A) (2013-current)

Chief Scientific Advisor, E.O. Bio Pvt Ltd. (2022-present)

Lockheed’s Martin Talent Network (2022- present)

Mentor, KIIT Animal and Environment Welfare Society (2022- present)

Amgen Talent (2019—present)

Moderator, Express Pharma, Dec 2021

Editorial Board, IJPPT, 2021-present

Editorial Board, CCLSJ, 2021-present

Represented India in “ICONBACC 2021, Misamis University, Philippines

Selection Committee member, Pantheon Award, 2021

Amgen Talent (2019—present)

Moderator, Express Pharma, Dec 2021

Editorial Board, IJPPT, 2021-present

Editorial Board, CCLSJ, 2021-present

Represented India in “ICONBACC 2021, Misamis University, Philippines

Selection Committee member, Pantheon Award, 2021

Recipient of Biotechnology Ignition Grant (BIG) for multi-drug resistance (2014-current)

Recipient of MSME Award for development of culture media for CHO DG44 cells ( 2013-Current)

Jury, Biotech Projects, Confederation Of Indian Industries (C.I.I)(2013-current)

Advisor, Technology Commercialization Facilitation Agency (T.C.F.A) (2013-current)

Member, Indian Science Congress (2013-present)

Head, Technology & Translational Research, KIIT-TBI, KIIT University, Bhubaneswar, Orissa (2013-current)

Consulting Director Position Offer, Intas Pharmaceuticals Ltd.

Consultant , Sun Pharmaceuticals Ltd.(2010-11)

General Manager, Biotechnology Research Laboratory, USV.(1995-2010)

Member, Mayo Clinic Alumni(1994-current)

Swiss Post Doctoral Fellowship, 1993-4

Instructor, Genetics, Virginia Tech (1991)

NIH Postdoctoral Fellowship, 1992-3

NIH Graduate Fellowship, 1986-91

Member, St. Stephens College Alumni(1982-current)

Member, Bhavanite, Bharatya Vidya Bhavan Alumni(1977-current)

Long Service Award : USV Ltd. ( 1996-2006)

Tata Endowment Scholar 1986

Dept. Of Atomic Energy Fellowship BARC (1983-1985)

Instructor, Physics, St. Stephen’s College, Delhi University ( 1982)

Instructor, Physics, Hindu College, Delhi University(1983)

National Science Scholarship ( 1980-1982)

School topper, Kulpati K.M. Munshi Gold Medal For Science(1977)

School captain, BVB Public School, Kasturba Gandhi Marg, (1976-77)

Letters Of Appreciation from Nobel Laureate, and President Of U.S.A

Letter Of Appreciation from Center For Disease Control, USA

@ E.O Bio Pvt Ltd (Genome editing of immune cells for anti-cancer regimen of solid tumors, 2022- present)

@ KIM’s Hospital, BBSR (In vitro model of sepsis, role of topoisomerase inhibitors, DNA gyrase inhibitors, 30 S subunit inhibition, and 50 S subunit inhibition, 2022-present)

@ UCSF (Platform troubleshoot2021-present)

@ Start up (CART Therapy platform)

* If you have health anxiety write to us @: yourtearsmine@gmail.com

(stories in blog)